コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ells from patients with paroxysmal nocturnal hemoglobinuria.
2 number of patients with paroxysmal nocturnal hemoglobinuria.
3 pe of the human disease paroxysmal nocturnal hemoglobinuria.
4 ntage of blood cells in paroxysmal nocturnal hemoglobinuria.
5 ficacy in patients with paroxysmal nocturnal hemoglobinuria.
6 onephritis type II, and paroxysmal nocturnal hemoglobinuria.
7 ted HTRs, exemplified by rapid clearance and hemoglobinuria.
8 ment, leading to intravascular hemolysis and hemoglobinuria.
9 ells from patients with paroxysmal nocturnal hemoglobinuria.
10 for reported cases of hemoglobinemia and/or hemoglobinuria.
11 s from the pounding of feet on pavement, and hemoglobinuria.
12 inance in patients with paroxysmal nocturnal hemoglobinuria.
13 n approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by p
14 carried a diagnosis of paroxysmal nocturnal hemoglobinuria, a relative contraindication for liver tr
15 phocyte pool; in AA and paroxysmal nocturnal hemoglobinuria, a seemingly random overrepresentation of
16 has been recognized as paroxysmal nocturnal hemoglobinuria, an acquired clonal disorder associated w
17 atment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
18 oplan and eculizumab in paroxysmal nocturnal hemoglobinuria and discuss the complement-mediated disea
22 anti-D-IGIV-associated hemoglobinemia and/or hemoglobinuria and provides pretreatment and posttreatme
24 protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an as
25 th sickle cell disease, paroxysmal nocturnal hemoglobinuria, beta-thalassemia major, or thalassemia i
26 on the hypothesis that paroxysmal nocturnal hemoglobinuria cells are more sensitive to APC-activated
27 and those with expanded paroxysmal nocturnal hemoglobinuria clones showed more skewed VB repertoires.
28 ment inhibitors include paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, hemolytic uremi
29 that FB28.4.2 protected paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hem
31 fic diseases, including paroxysmal nocturnal hemoglobinuria (erythrocytes), atypical hemolytic uremic
32 ents who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for
33 DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for
34 received 15 reports of hemoglobinemia and/or hemoglobinuria following anti-D IGIV administration that
35 ells from patients with paroxysmal nocturnal hemoglobinuria in either the acidified serum or "sugar w
36 emolysis suffering from paroxysmal nocturnal hemoglobinuria in which the acquired mutation in the PIG
37 emolytic states such as paroxysmal nocturnal hemoglobinuria, in which plasma hemoglobin concentration
40 tic, defining defect in paroxysmal nocturnal hemoglobinuria is the somatic mutation of the PIG-A gene
42 ue for the diagnosis of paroxysmal nocturnal hemoglobinuria; it is clearly more specific, more quanti
43 plasms, acute leukemia, paroxysmal nocturnal hemoglobinuria, mast cell disease, myelodysplastic syndr
44 -A genes in humans with paroxysmal nocturnal hemoglobinuria may be subject to comparable pathophysiol
45 , anemia, elevated liver function tests, and hemoglobinuria-may be especially severe in asplenic or i
46 diated disease model of paroxysmal nocturnal hemoglobinuria, mini-FH largely outperformed FH and indi
47 lonal disorder, such as paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, or leukemia.
49 e, cold agglutinin syndrome, paroxysmal cold hemoglobinuria, or autoimmune hemolytic anemia secondary
51 with the PIG-A mutant (paroxysmal nocturnal hemoglobinuria) phenotype at a median frequency (f) of a
52 amined 19 patients with paroxysmal nocturnal hemoglobinuria (PNH) (18 with active disease and 1 spont
53 ng clinical conditions: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndr
54 (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndr
55 ls to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndr
56 e principal features of paroxysmal nocturnal hemoglobinuria (PNH) and constitutes the main cause of d
57 revent complications of paroxysmal nocturnal hemoglobinuria (PNH) and improve quality of life and ove
58 (-) cells in 2 cases of paroxysmal nocturnal hemoglobinuria (PNH) and some myeloproliferative neoplas
59 the natural history of paroxysmal nocturnal hemoglobinuria (PNH) and to review new therapeutic strat
60 plastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are pathogenically related nonmalig
64 mic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) as well as thrombin generation in p
65 Cy arm had evidence of paroxysmal nocturnal hemoglobinuria (PNH) at diagnosis, with no substantial c
66 the genetic basis of a paroxysmal nocturnal hemoglobinuria (PNH) case without somatic mutations in P
69 has been proposed that paroxysmal nocturnal hemoglobinuria (PNH) cells may proliferate through their
70 cells in patients with paroxysmal nocturnal hemoglobinuria (PNH) comprise a mixture of residual norm
71 cells in patients with paroxysmal nocturnal hemoglobinuria (PNH) comprise variable mixtures of norma
74 netic defect underlying paroxysmal nocturnal hemoglobinuria (PNH) has been shown to reside in PIGA, a
100 he clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is chronic intravascular hemolysis
103 distinctive feature of paroxysmal nocturnal hemoglobinuria (PNH) is that in each patient glycosylpho
106 myelodysplasia (MDS) or paroxysmal nocturnal hemoglobinuria (PNH) occurring as a late complication of
107 rring in a patient with paroxysmal nocturnal hemoglobinuria (PNH) on treatment with anticomplement th
108 complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment.
109 f 35 AA, 37 MDS, and 21 paroxysmal nocturnal hemoglobinuria (PNH) patients, in whom specific CDR3 seq
110 rom the erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) patients, who suffer from complemen
111 A 10-year-old girl with paroxysmal nocturnal hemoglobinuria (PNH) received an infusion of syngeneic b
112 third of patients with paroxysmal nocturnal hemoglobinuria (PNH) remain transfusion dependent or hav
113 the hematologic disease paroxysmal nocturnal hemoglobinuria (PNH) remains the prototypic model of com
115 ytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) undergoing eculizumab treatment, wh
116 eport on a patient with paroxysmal nocturnal hemoglobinuria (PNH) who does not have a mutation of PIG
117 ets of 54 patients with paroxysmal nocturnal hemoglobinuria (PNH) with antibodies to glycosylphosphat
118 tient to be treated for paroxysmal nocturnal hemoglobinuria (PNH) with syngeneic bone marrow transpla
119 ement-mediated lysis in paroxysmal nocturnal hemoglobinuria (PNH), a disease that manifests after clo
120 clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening hemato
124 g aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), and some forms of myelodysplasia (
125 d macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome
127 ells from patients with paroxysmal nocturnal hemoglobinuria (PNH), leading to deficiency of GPI-linke
128 rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a defi
129 e hematological disease paroxysmal nocturnal hemoglobinuria (PNH), to the common blinding disease age
137 ytes from patients with paroxysmal nocturnal hemoglobinuria (PNH); the authors demonstrate that these
138 cytes that recapitulate paroxysmal nocturnal hemoglobinuria, PspCN enhanced protection of cells by FH
140 molytic anemias such as paroxysmal nocturnal hemoglobinuria, sickle cell disease, and thalassemia.
142 molytic anemia syndrome paroxysmal nocturnal hemoglobinuria, the in vivo biology of DAF is still poor
144 ytes from patients with paroxysmal nocturnal hemoglobinuria, which lack glycosylphosphatidylinositol-
145 enges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have
146 , schistocytosis, free hemoglobin in plasma, hemoglobinuria with hemosiderinuria, and platelet activa